A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EP / EndoPredict

[Related PubMed/MEDLINE]
Total Number of Papers: 18
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EP  (>> Co-occurring Abbreviation)
Long Form:   EndoPredict
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. BC
2019 Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. FFPE, HER2, LumA, LumB, ROR, RS
2019 Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. DRFR, ER
2019 Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score (RS) assay and other genomic assays for early breast cancer. BCI, EBC, EPclin, MMP, RS
2018 Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option? BCI, MBC, NCCN
2018 First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. ER, FFPE, HER2, QA
2018 Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value. CRR, pCR, PEPI
2018 Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. CI, DFS, ER, mEPclin, NACT
2017 MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer. MP
10  2016 Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. BC, ET, MFS, ROR, ROR-PT, ROR-T
11  2016 [A Review Multigene Assays for Clinical Utility in Breast Cancer]. BCI
12  2015 The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. BCT, LR, RT
13  2014 Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. BC, CI, FEC, FEC-P, HR, MFS, PR
14  2014 EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. pCR
15  2013 Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. RS
16  2013 The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. DM
17  2012 Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. ---
18  2012 Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. FFPE, RT-qPCR